



Factsheet: Neurotech International

Neurotech International (Neurotech)(ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Our current clinical programs give genuine hope to families who have children diagnosed with severe Autism (ASD), PANS/ PANDAS¹, Rett syndrome and cerebral palsy.

We are dedicated to making a positive impact on the field of neurology and improving the lives of those affected by neurological disorders through our four core strategies:

Our 4 core strategies:



Focus on Paediatric Patients



Focus On Rare Neurological Disorders with Neuroinflammation



Focus on Partnering with Key Opinion Leaders / Clinicians



Focus On Drug Product Development

- 1. Focus on paediatric patients:** our work is centred around providing care and treatment for children.
- 2. Focus on ASD and rare neurological disorders with neuroinflammation:** we aim to provide much-needed solutions for patients with complex and often overlooked conditions.
- 3. Focus on Partnering with Key Opinion Leaders / Clinicians:** placing emphasis on partnering with key opinion leaders and clinicians, allowing us to collaborate with experts and stay up to date with the latest developments in neurological research.
- 4. Focus on drug product development:** creating innovative, effective pharmaceutical products for neurological disorders.

NTI164 – EXCLUSIVE GLOBAL LICENCE FOR NEUROLOGICAL APPLICATIONS

NTI164 is a medicinal cannabis derived biopharmaceutical. It provides all the beneficial properties and components of ‘full-spectrum’ cannabis (not CBD) without Tetrahydrocannabinol (THC), the substance primarily responsible for the “high” effect on a person's mental state.

¹ Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) / Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)



NTI164 has multi-functional modes of action: neuro-protection, neuro-modulation and neuro-regulation. Grown in Australia under strict horticultural conditions that ensure its integrity, NTI164 has a high level of cannabidiolic acid (CBDA) and an assortment of other minor cannabinoids such as CBG, CBN and CBDP. NTI164’s unique combination works differently to CBD and has powerful effects on inflammatory pathways.


Preclinical and clinical studies to date have shown that NTI164 is a powerful neuro-anti-inflammatory modulator, can suppress a wide range of inflammatory cytokines, and improves neuronal cell viability and overall health.

There is a strong market need for an effective therapeutic intervention such as NTI164 to improve symptoms of paediatric neurological disorders such as autism spectrum disorder (ASD), PANS/PANDAS¹, Rett syndrome and cerebral palsy to reduce healthcare costs and offer treatments without significant side effects. It also has the potential to reduce the burden on government-funded schemes; current estimates have paediatric ASD costing Australia’s National Disability Insurance Scheme (NDIS) \$8.25 billion.



STRATEGIC CLINICAL PROGRAM MAXIMISING REGULATORY LEVERS

Clinical Pipeline – 2023





Neurotech's clinical program is phased and focused, with a mapped-out strategy from development to implementation designed to meet regulatory requirements in the USA, EU, UK and Australia. Clinical development is accelerated via rapid and cost-effective proof of concept Phase I/II clinical trials in Australia for new paediatric neurological disorders.

CASE STUDY: NTI164 AND ASD

WORLD FIRST HUMAN CLINICAL STUDY TO TREAT ASD

Neurotech's world's first medicinal cannabis derived biopharmaceutical, NTI164, has been successfully studied in children with ASD. The Phase I/II study was conducted by Professor Michael Fahey, Head of Paediatric Neurology at Monash Children's Hospital, Melbourne, and demonstrated that treatment with NTI164 is associated with statistically significant and clinically meaningful symptom improvement relating to severity of illness, social behaviour and communication.

Data shows children taking NTI164 daily experienced marked improvement with socialisation, attendance at school, and classroom behaviour. These children also experienced improvement to their levels of anxiety, irritability and hyperactivity.¹

The side effects reported were not serious or severe and did not significantly interfere with patients' functioning.¹ Importantly, there was no evidence that prolonged use of NTI164 in these patients can lead to any form of therapeutic tolerance as measured by a slow reversion of symptoms through extended use,¹ which highlights chronic administration of NTI164 is required to achieve significant improvements in clinical outcome measures.

NTI164 PROVIDING ECONOMIC SOLUTIONS

Neurotech is working towards providing economic solutions for healthcare systems worldwide. In Australia, the National Disability Insurance Scheme (NDIS) helps people with a disability, their families and carers.

In 2022, the NDIS cost \$35.5 billion and that is expected to increase to \$52 billion by 2026 and \$100 billion by 2033.² 34% of the 550,000 NDIS participants have ASD, with 40% ≤ 14 years old (860,000 by 2030).³



National Disability
Insurance Scheme



\$8.25 billion is the implied annual cost of ASD to the NDIS based on average ASD funding of \$32,800 per annum e.g. physio, psychology, speech therapy, occupational therapy and support workers.⁴ There is a strong market need for an effective therapeutic intervention such as NTI164 to improve ASD symptoms & reduce healthcare costs.²

Visit <http://www.neurotechinternational.com> for more information.

REFERENCES

1. 1NTI164 Clinical Trial, results on file. <https://www.investi.com.au/api/announcements/nti/88fe63d6-dcf.pdf>
2. The Australian, 25 October, 2022- <https://www.afr.com/politics/federal/how-the-ndis-will-blow-out-to-50b-in-four-charts-20221019-p5br1c>
3. <https://www.uwa.edu.au/news/Article/2022/August/An-autism-minister-may-boost-support-and-coordination-But-governments-that-follow-SAs-lead-should-be-cautious>
4. <https://www.theaustralian.com.au/weekend-australian-magazine/autism-will-cost-the-budget-825bn-via-the-ndis-will-the-safety-net-break/news-story/30431ced5d93b62f8c353407896606f8>
5. <https://disabilityplanservices.com.au/blog/how-much-is-ndis-funding-for-autism/#:~:text=At%20Disability%20Plan%20Services%2C%20we,per%20year%20under%20the%20NDIS>

¹Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS)